Statement: Patients participating in the primary trial and the secondary trial experienced serious eye disorders.
Primary_evidence: Adverse Events 1:   Total: 1/3 (33.33%)   Pericardial effusion  [1]0/3 (0.00%)   Abdominal muscle wall hemorrhage  [2]0/3 (0.00%)   Dehydration  [3]0/3 (0.00%)   Gastroenteritis 0/3 (0.00%)   Dehydration 0/3 (0.00%)   Vomiting  [4]0/3 (0.00%)   Colonic perforation  [5]0/3 (0.00%)   Abdominal pain 0/3 (0.00%)   Chemical meningitis 0/3 (0.00%)   Lung infection 0/3 (0.00%)   Wound infection 0/3 (0.00%) Adverse Events 2:   Total: 2/3 (66.67%)   Pericardial effusion  [1]0/3 (0.00%)   Abdominal muscle wall hemorrhage  [2]0/3 (0.00%)   Dehydration  [3]0/3 (0.00%)   Gastroenteritis 0/3 (0.00%)   Dehydration 0/3 (0.00%)   Vomiting  [4]0/3 (0.00%)   Colonic perforation  [5]0/3 (0.00%)   Abdominal pain 0/3 (0.00%)   Chemical meningitis 0/3 (0.00%)   Lung infection 0/3 (0.00%)   Wound infection 1/3 (33.33%)
Secondary_evidence: Adverse Events 1:   Total: 148/1755 (8.43%)   Anaemia * 1/1755 (0.06%)   Neutropenia * 0/1755 (0.00%)   Thrombocytopenia * 0/1755 (0.00%)   Thrombocytopenic purpura * 1/1755 (0.06%)   Acute cardiac event * 1/1755 (0.06%)   Aortic valve incompetence * 1/1755 (0.06%)   Arrhythmia * 1/1755 (0.06%)   Atrial fibrillation * 1/1755 (0.06%)   Cardiac failure * 0/1755 (0.00%)   Cardiac tamponade * 0/1755 (0.00%) Adverse Events 2:   Total: 64/868 (7.37%)   Anaemia * 2/868 (0.23%)   Neutropenia * 2/868 (0.23%)   Thrombocytopenia * 1/868 (0.12%)   Thrombocytopenic purpura * 0/868 (0.00%)   Acute cardiac event * 0/868 (0.00%)   Aortic valve incompetence * 0/868 (0.00%)   Arrhythmia * 1/868 (0.12%)   Atrial fibrillation * 0/868 (0.00%)   Cardiac failure * 1/868 (0.12%)   Cardiac tamponade * 1/868 (0.12%)